Alpha Cognition Inc.
ACOG•NASDAQ•Healthcare•Biotechnology

About Alpha Cognition

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMichael McFadden
Founded2000
CountryCanada
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.alphacognition.com
Phone604 564 9244
Address
750 West Pender Street, Suite 1200 Vancouver, BC V6C 2T8 Canada

Corporate Identifiers

CIK0001655923
ISINCA02074J5017
SIC2836

Leadership Team & Key Executives

Michael E. McFadden B.B.A.
Chief Executive Officer and Director
Lauren D'Angelo M.B.A.
Chief Operating Officer
Kenneth Anthony Cawkell B.A., LL.B.
Founder, Consultant, Corporate Secretary and Director
Henry Du CPA
Vice President of Finance and Accounting and Interim Chief Financial Officer
Dr. Denis G. Kay M.Sc., Ph.D.
Chief Scientific Officer
Timothy Ayers
Head of Compliance
Amy Kincaid
Executive Director, Head of Marketing and Commercial Strategy
Jack Kelly
Executive Director and Head of Market Access